Staladex® is a long acting implant formulation of leuprorelin indicated in men for the treatment of prostate cancer.
Staladex® should only be administered by a healthcare professional.
Staladex® is a Prescription Only Medicine. Prescription-only medicines, must be prescribed by a qualified health professional. This may be a GP or hospital doctor for example.
Each implant contains 11.25 mg leuprorelin acetate (equivalent as 10.72 mg leuprorelin). Always read the label
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Patients and Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Typharm on 02037 694160.